{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:48:38Z","timestamp":1760982518353},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,2,26]],"date-time":"2008-02-26T00:00:00Z","timestamp":1203984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:p>Recent case\u2013series studies indicated that a medication used to treat Parkinson\u2019s disease (PD), in particular Pramipexole, is associated with gambling. A case\u2013series study cannot test this hypothesis; therefore, we need to design a case\u2013control or cohort study to test the aforementioned hypothesis. Typical of a case\u2013control design, we sampled on the dependent variable, which we defined as incident gambling in PD. A research neurologist, who was kept uninformed of the case\u2013control status, retrospectively measured the exposure of interest (i.e. medications used to treat PD) by using the medical database system of Mayo Clinic Jacksonville. Eleven patients with PD without history of gambling, but had newly developed gambling, were matched by age and sex to the control group of 37 PD patients without gambling at a ratio of one case to at least three controls. Disease duration, age, and sex did not differ between cases and controls. Combined therapy with Pramipexole and levodopa did not increase the risk of gambling as compared to monotherapy with Pramipexole (OR, 0.15; 95% CI, 0.01\u20131.26). Treatment with Pramipexole was associated with increased risk of gambling and this association approached significance (OR, 3.6; 95% CI, 0.9\u201314.9). Patients with PD who newly developed gambling behavior were more likely to have been taking Pramipexole than other anti\u2010PD medication. However, the association between Pramipexole and gambling behavior is <jats:italic>not<\/jats:italic> necessarily etiologic.<\/jats:p>","DOI":"10.1111\/j.1468-1331.2008.02081.x","type":"journal-article","created":{"date-parts":[[2008,2,26]],"date-time":"2008-02-26T09:31:42Z","timestamp":1204018302000},"page":"350-354","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Medications used to treat Parkinson\u2019s disease and the risk of gambling"],"prefix":"10.1111","volume":"15","author":[{"given":"A.","family":"Imamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. E.","family":"Geda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Slowinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z. K.","family":"Wszolek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Uitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,2,26]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1993.00540080076020"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.262.18.2599"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000238503.20816.13"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21072"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.9.noc50009"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.4.423"},{"key":"e_1_2_7_9_2","first-page":"153","volume-title":"Recent Development in Parkinson\u2019s Disease","author":"Fahn S","year":"1987"},{"key":"e_1_2_7_10_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset progression and mortality","volume":"17","author":"Hoen M","year":"1967","journal-title":"Neurology"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.70.4.464"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.1.85"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2004.10.007"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.1.33"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00268a044"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000076478.45005.EC"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10625"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000218206.20920.4d"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.02.004"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.08.003"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.020982"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I"},{"key":"e_1_2_7_24_2","volume-title":"Epidemiology: Beyond the Basics","author":"Szklo M","year":"2000"},{"key":"e_1_2_7_25_2","first-page":"141","article-title":"Pharmacology of pramipexole, a dopamine D\u20103 preferring agonist useful for the treatment of Parkinson\u2019s disease","volume":"21","author":"Piercey MF","year":"1998","journal-title":"Clinical Neuropharmacology"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2008.02081.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2008.02081.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T01:46:12Z","timestamp":1696902372000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2008.02081.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,26]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1468-1331.2008.02081.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02081.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,26]]},"assertion":[{"value":"2008-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}